Sirius Workforce Development Revenue and Competitors

Theodore, AL USA

Location

N/A

Total Funding

HR

Industry

Estimated Revenue & Valuation

  • Sirius Workforce Development's estimated annual revenue is currently $100.5k per year.(i)
  • Sirius Workforce Development's estimated revenue per employee is $100,500

Employee Data

  • Sirius Workforce Development has 1 Employees.(i)
  • Sirius Workforce Development grew their employee count by -50% last year.

Sirius Workforce Development's People

NameTitleEmail/Phone
1
Director Workforce DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.1M130-1%N/AN/A
#2
$3.8M274%N/AN/A
#3
$23.1M115-4%N/AN/A
#4
$75.9M3027%N/AN/A
#5
$6.9M435%N/AN/A
#6
$43.8M198N/AN/AN/A
#7
$38.3M1737%N/AN/A
#8
$24.1M12020%N/AN/A
#9
$0.1M1-50%N/AN/A
#10
$7.4M462200%N/AN/A
Add Company

What Is Sirius Workforce Development?

Sirius Workforce Development is committed to strengthening the US labor market through the support of federal, state, local, and corporate programs targeted at job creation (training, development, and placement). Sirius brings proven, scalable, and robust back-office functions (HR, payroll, benefits) which compliment the mission focused work of our clients and partners. We are devoted to bolstering the efficiency and effectiveness of organizations who support underserved communities.

keywords:N/A

N/A

Total Funding

1

Number of Employees

$100.5k

Revenue (est)

-50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sirius Workforce Development News

2022-04-13 - ProQR to Cut 30% of Workforce, CSO Following Unexpected ...

Netherlands-based ProQR Therapeutics, which is developing RNA ... a readout of the Phase II/III Sirius clinical trial of ultevursen,...

2022-04-13 - ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce - Benzinga

has decided to prioritize the development of genetic eye disease ... and retinitis pigmentosa on a single Phase 2/3 Sirius trial with the...

2022-04-13 - ProQR Announces Additional Sepofarsen Illuminate Trial ...

Genetic eye diseases – Explore development path for selected ophthalmology ... readout of the modified Phase 2/3 Sirius trial of ultevursen.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.3M2-94%N/A
#2
$0.6M525%N/A
#3
$0.5M70%N/A
#4
$4.1M20-50%N/A
#5
$4.3M230%N/A